Arthneeti
VS

Viyash Scientific Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Viyash Scientific Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹276
Market cap₹11.2K Cr
P/E50.8
Updated23 Aug 2026
Read5 min read

The short version

API business expected to grow at a double-digit rate going forward, driven by quality APIs (human and animal health) and new approvals coming this year and next (Page 17). - Formulation business also anticipated to grow strongly, particularly animal health formulations with significant R&D and capex expansion (Page 17). - Targeting overall revenue growth of around 15% annually over the next few years (Page 15). - Animal health segment showing strong growth after years of being stable; run rate increased from ~INR350 crores to INR400 crores, with further growth expected (Page 4). - CDMO business projected to grow 30-40% next year, supported by 8-10 innovator clients and multiple product approvals underway (Page 5). - Focus on expanding into European companion animal market (~$1 billion) and preparing for entry into the U.S. EBITDA expected to grow from INR700 crores to around INR1,000 crores in next 2-3 years, targeting FY27/FY28.

From Viyash Scientific Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • API business expected to grow at a double-digit rate going forward, driven by quality APIs (human and animal health) and new approvals coming this year and next (Page 17).
  • Formulation business also anticipated to grow strongly, particularly animal health formulations with significant R&D and capex expansion (Page 17).
  • Targeting overall revenue growth of around 15% annually over the next few years (Page 15).
  • Animal health segment showing strong growth after years of being stable; run rate increased from ~INR350 crores to INR400 crores, with further growth expected (Page 4).
  • CDMO business projected to grow 30-40% next year, supported by 8-10 innovator clients and multiple product approvals underway (Page 5).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Viyash Scientific Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Significant capex planned for capacity expansion, especially in animal health formulation and finished product formulation (human health and companion animals).
  • Investment in R&D expansion with focus on adding more scientists, particularly in specialized human health formulation and animal health formulation teams.
  • Development of dedicated potent lab for oncology product R&D expected to be ready soon (this or next quarter).
  • Manufacturing expansion ongoing in Spain and debottlenecking at Turkey manufacturing to support future growth.
  • Capex already done in Viyash for capacity increase, awaiting approvals to realize further synergy benefits.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Viyash Scientific Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention specific figures or details related to the current or expected order book or pending orders for Viyash Scientific Limited. However, relevant points indicating business outlook and growth include: - The CDMO business is working with 8 to 10 large innovator clients with several product approvals expected starting end of the current year. - The company anticipates a reasonable number of product approvals this year, supporting top-line and bottom-line growth. - Growth in the animal health segment, especially companion animal generics in Europe and other markets, is increasing with a $1 billion addressable opportunity. - Expected EBITDA growth targets point to a CAGR of around 15%, suggesting increasing business volume.

2 more points management made on order book & pipeline

Viyash Scientific Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Viyash Scientific's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

  • Morepen Laboratories Ltd (Q4 FY26)

    472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…

  • Anuh Pharma Ltd (Q4 FY26)

    202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…

  • Themis Medicare Ltd (Q4 FY26)

    Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Viyash Scientific Ltd Q4 FY26 results?

API business expected to grow at a double-digit rate going forward, driven by quality APIs (human and animal health) and new approvals coming this year and next (Page 17). - Formulation business also anticipated to grow strongly, particularly animal health formulations with significant R&D and capex expansion (Page 17). - Targeting overall revenue growth of around 15% annually over the next few years (Page 15). - Animal health segment showing strong growth after years of being stable; run rate increased from ~INR350 crores to INR400 crores, with further growth expected (Page 4). - CDMO business projected to grow 30-40% next year, supported by 8-10 innovator clients and multiple product approvals underway (Page 5). - Focus on expanding into European companion animal market (~$1 billion) and preparing for entry into the U.S. EBITDA expected to grow from INR700 crores to around INR1,000 crores in next 2-3 years, targeting FY27/FY28.

What is Viyash Scientific Ltd share price analysis?

Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹11,246 Cr. Investors should review the full earnings analysis for detailed insights.

Is Viyash Scientific Ltd planning capital expenditure?

Significant capex planned for capacity expansion, especially in animal health formulation and finished product formulation (human health and companion animals).

Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.